S. Khostelidi, V. A. Zaytsev, E. V. Pelikh, É. Yashina, O.N. Rodionova, T. Bogomolova, Y. Avdeenko, N. Klimko
{"title":"covid - 19后毛霉菌病:临床病例及文献复习","authors":"S. Khostelidi, V. A. Zaytsev, E. V. Pelikh, É. Yashina, O.N. Rodionova, T. Bogomolova, Y. Avdeenko, N. Klimko","doi":"10.36488/cmac.2021.3.255-262","DOIUrl":null,"url":null,"abstract":"Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in Russia after infection caused by SARS-CoV-2, as well as a review of literature reports on mucormycosis in patients with COVID-19 (as of September 2021).","PeriodicalId":53392,"journal":{"name":"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"5","resultStr":"{\"title\":\"Mucormycosis following COVID19: clinical case and literature review\",\"authors\":\"S. Khostelidi, V. A. Zaytsev, E. V. Pelikh, É. Yashina, O.N. Rodionova, T. Bogomolova, Y. Avdeenko, N. Klimko\",\"doi\":\"10.36488/cmac.2021.3.255-262\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in Russia after infection caused by SARS-CoV-2, as well as a review of literature reports on mucormycosis in patients with COVID-19 (as of September 2021).\",\"PeriodicalId\":53392,\"journal\":{\"name\":\"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36488/cmac.2021.3.255-262\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Klinicheskaia mikrobiologiia i antimikrobnaia khimioterapiia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36488/cmac.2021.3.255-262","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Mucormycosis following COVID19: clinical case and literature review
Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in Russia after infection caused by SARS-CoV-2, as well as a review of literature reports on mucormycosis in patients with COVID-19 (as of September 2021).